The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time

Summary

The interaction between von Willebrand factor (VWF) and platelet glycoprotein Ibα (GPIbα) is a critical step that allows platelet adhesion, activation and subsequent thrombus formation to the injured vessel wall under high-shear conditions. In this study, we sought to investigate 1) whether GPG-290, a recombinant human GPIbα chimeric protein, would prevent thrombosis in a canine model of coronary thrombosis by blocking VWFGPIbα interaction; and 2) whether desmopressin (DDAVP), a VWF release stimulant, could reduce the prolonged bleeding time caused by a 10x efficacious dose of GPG-290. The antithrombotic efficacy of GPG-290 was evaluated by the in-vivo ability to prevent cyclic flow reductions (CFRs) and ex-vivo inhibition of platelet adhesion/aggregation reflected by prolongation of Platelet Function Analyzer (PFA-100^®) collagen /ADP closure time. The anti-hemostatic effect was assessed by template bleeding time. GPG-290 at doses of 25, 50 and 100 μg/kg abolished CFRs in 67%,100% and 100% of the treated dogs without bleeding time prolongation, respectively; GPG-290 dose-dependently prolonged the ex-vivo collagen/ADP-closure time, while it had no effects on plasma VWF antigen level (VWF:Ag) and VWF-collagen binding activity (VWF:CB); the prolonged template bleeding time caused by 500 μg/kg of GPG-290 was prevented by intravenous infusion of DDAVP (0.3 μg/kg). In conclusion, GPG-290 appears to be an effective agent for treating arterial thrombosis without bleeding time prolongation.

Keywords

Glycoprotein (GP) Ibα - DDAVP - vonWillebrand factor - thrombosis - platelet adhesion/activation

• References

• 1 McNicol A, Israels SJ. Platelets and anti-platelet therapy. J Pharmacol Sci 2003; 93: 381-396.
• 2 Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 1985; 53: 363-373.
• 3 Bonnefoy A, Vermylen J, Hoylaerts MF. Inhibition of von Willebrand factor-GPIb/IX/V interactions as a strategy to prevent arterial thrombosis. Expert Rev Cardiovasc Ther 2003; 1: 257-269.
• 4 Penz SM, Reininger AJ, Toth O. et al. Glycoprotein Ibα inhibition and ADP receptor antagonists, but not aspirin, reduceplateletthrombus formation in flowing blood exposed to atherosclerotic plaues. Thromb Haemost 2007; 97: 435-443.
• 5 Pontiggia L, Steiner B. Ulrichts et al. Platelet microparticle formation and thrombingeneration under high shear are effectively suppressed by a monoclonal antibodyagainst GPIbα. Thromb Haemost 2006; 96: 774-780.
• 6 Andrews RK, López JA, Berndt MC. Molecular mechanisms of platelet adhesion and activation. Int J Biochem Cell Biol 1997; 29: 91-105.
• 7 Lopez JA. The platelet glycoprotein Ib-IX complex. Blood Coag Fibrinol 1994; 5: 97-119.
• 8 Huizinga EG, Tsuji S, Romijn RAP. et al. Structures of GPIbα and its complex with the vWF-A1-domain. Science 2002; 297: 1176-1179.
• 9 Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2004; 1: 1602-1612.
• 10 Kroll MH, Hellums JD, McIntire LV. et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
• 11 Hennan JK, Swillo RE, Morgan GA. et al.. Pharmacologic inhibition of platelet vWF-GPIbα interaction prevents coronary artery thrombosis. Thromb Haemost 2006; 95: 469-475.
• 12 Mannucci PM. Management of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 602-609.
• 13 Folts JD, Edward B, Crowell J. et al. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
• 14 Krizek Dr, Rick KM. A rapid method to visualize von Willebrand factor multimers by using gel electro-phoresis, immunolocalization and luminographic detection. Thromb Res 2000; 97: 457-462.
• 15 Schaub RG, Rawlings CA, Keith Jr JC. Plateletadhesion and myointimalproliferation in canine pulmonaryarteries. Am J Pathol 1981; 104: 13-22.
• 16 Ikeda H, Koga Y, Kuwano K. et al. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans. J Am Coll Cardiol 1993; 21: 1008-1017.
• 17 Willerson JT, Yao SK, McNatt J. et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci USA 1991; 88: 10624-10628.
• 18 McGhie AI, McNatt J, Ezov N. et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasmavon Willebrand factor-glycoprotein Ib binding domain. Circulation 1994; 90: 2976-2981.
• 19 Kageyama S, Yamamoto H, Nagano M. et al. Antithrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor. Br J Pharmacol 1997; 122: 165-171.
• 20 Kageyama S, Yamamoto H, Nakazawa H. et al. Antihuman vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395-404.
• 21 Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in acanine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-149.
• 22 Andrews RK, Shen Y, Gardiner EE. et al. The glycoprotein Ib-IX-V complex in platelet adhesion and signaling. Thromb Haemost 1999; 82: 357-364.
• 23 Wang Q, Shaw G, Shorten D. et al. The effect of von Willebrand factor on the disposition of GPIbα-Ig in lab animals. AAPS PharmSci 2003; 5: R6182 Abstract.
• 24 Smith Jr SC, Dove JT, Jacobs AK. et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines):executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
• 25 Mammen EF, Comp PC, Gosselin R. et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195-202.
• 26 Watala C, Golanski J, Rozalski M. et al. Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100?. Thromb Res 2003; 109: 299-306.
• 27 Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Hemost 2003; 1: 682-689.
• 28 Mannucci PM. Desmopressin(DDAVP) in the treatment of bleeding disorders: The first 20 years. Blood 1997; 90: 2515-2521.
• 29 Bernat A, Hoffmann P, Dumas A. et al. V2 reveptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997; 282: 597-602.
• 30 Vilhardt H, Barth T. The release of factor VIII and tissue plasminogen activator cannot be blocked by specific antagonists to vasopressin. J Recept Res 1991; 11: 239-245.